CD8A and neoplasm: The nearly universal refractoriness of PDAC to T cell-based immunotherapies has been attributed to a low mutation burden predicted to generate very few immunogenic antigens and a complex immunosuppressive tumour microenvironment devoid of CD8+ T cells and their activation marker expression12.